En Es
Categories

Industry News

Luminex Acquires MilliporeSigma Flow Cytometry Portfolio

By Labmedica International staff writers
08 Jan 2019

Image: Luminex has acquired the flow cytometry portfolio of MilliporeSigma (Photo courtesy of iStock).Luminex Corporation (Austin, Texas, USA) has completed its previously announced acquisition of MilliporeSigma's (Burlington, MA, USA) flow cytometry portfolio.

Luminex offers a wide range of solutions applicable in diverse markets, including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. Luminex's newly acquired flow cytometry portfolio includes the Amnis family of imaging flow cytometry products for cell-based analysis, as well as the Guava portfolio of systems based on microcapillary technologies.

"We are pleased to announce the completion of this transaction and excited to welcome the talented MilliporeSigma flow cytometry team to the Luminex family," said Homi Shamir, president and CEO of Luminex. "This acquisition enables us to enhance our existing offering of flow-based detection systems, while simultaneously expanding our direct interactions with researchers conducting cellular analysis."

"The Amnis and Guava products complement our wide range of existing flow-based offerings, further differentiating our portfolio and ensuring we are well-positioned to support customers today and into the future," said Shamir. "With this acquisition, we now have expanded our installed based to include more than 5,000 flow cytometry systems worldwide, adding to our impressive footprint and creating the potential for additional meaningful growth."



E-mail Print
FaceBook Twitter Google+ Linked in

Luminex Corporation

Luminex develops, manufactures, and markets biological testing technologies with applications in clinical diagnostics, pharmaceutical drug discovery, biomedical research, including genomic and proteomic research, personalized medicine, biodefense research, and food safety. The company’s open-architecture xMAP technology enables large numbers of biological tests (bioassays) to be conducted and analyzed quickly, cost-effectively and accurately.
More info

Additional news

08 Jan 2019
New AI Technology Pinpoints Negative Symptoms in Cancer Patients
Researchers from the University of Surrey and the University of California have developed a new artificial intelligence (AI) tool, which can predict symptoms and their severity throughout the course of a cancer patient's treatment.
Read More
31 Dec 2018
Deep Learning Technique Could Reveal Transparent Features in Medical Images
Engineers at the Massachusetts Institute of Technology have developed a deep learning technique that can reveal images of transparent features or objects that are nearly impossible to decipher in almost total darkness.
Read More
31 Dec 2018
Next-Gen Products Driving Global POC Molecular Diagnostics Market
The global point of care (POC) molecular diagnostics market is expected to grow at a CAGR of close to 14% during the period 2019-2023, driven mainly by the growing number of M&As and collaborations, and rising focus on next-generation products.
Read More
31 Dec 2018
Increased Breast Cancer Driving Global Digital Breast Tomosynthesis Market
The global digital breast tomosynthesis market is expected to grow at a CAGR of around 13% for the period 2019-2023, driven by the increasing incidence of breast cancer, growing popularity of digital breast tomosynthesis and consistent launch of new products.
Read More
31 Dec 2018
Global Urinalysis Market to Reach USD 1.5 Billion by 2024
The global urinalysis market is expected to grow at a steady CAGR of 5.40% over the 2016-2024 period to reach a value of USD 1.5 billion by the end of 2024, propelled mainly by the rising incidence of diabetes and urinal infections, globally.
Read More
31 Dec 2018
Bruker Completes Acquisition of Alicona Imaging
Bruker Corporation has completed its previously announced acquisition of Alicona Imaging GmbH, a provider of optical-based metrology products.
Read More
25 Dec 2018
New AI-Based Solutions Create Possibility for Early Cancer Screening
Two new Artificial Intelligence- (AI) based products released at this year’s Radiological Society of North America (RSNA) annual meeting in Chicago, USA, could create possibility for large-scale early cancer screening globally.
Read More
25 Dec 2018
Network-Based AI Engine Performs Airway Segmentation from CT Images
A new 2.5D convolutional neural network (CNN)-based artificial intelligence (AI) engine enables accurate airway segmentation from computed tomography (CT) images without any human interaction.
Read More
25 Dec 2018
AI Software Pinpoints Biopsies to Detect Prostate Cancer
A team of engineers and medical researchers at the University College London have developed a medical software that overlays tumor information from MRI scans onto ultrasound images to help guide surgeons conducting biopsies (tissue sample) and improve prostate cancer detection. The software is deployed via a system called SmartTarget and enables surgeons to pick up clinically relevant cancers that were missed when using current visual detection methods.
Read More
Copyright © 2000-2019 TradeMed.com. All rights reserved. | Terms And Conditions